FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

if no longer subject to m 4 or Form 5	STATE

MENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287

Check this box

obligati لــــ	n 16. Form 4 or ons may contir tion 1(b).			Filed							es Exchanç npany Act o			934			ll ll		ed average burd er response:	en 0.5
						2. Issuer Name and Ticker or Trading Symbol CytomX Therapeutics, Inc. [CTMX]								Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner						
(Last) (First) (Middle) I					3. Date of Earliest Transaction (Month/Day/Year) 07/13/2017										Office below	er (give title v)	е	Other below	(specify	
(Street) BOSTON			02116 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person								
	`			n-Deriva	ative	Se	curitie	s Acc	uired.	Disi	nosed o	f. o	r Ber	nefici	ally	Owne	ed			
Date			2. Transa Date			2A. Deemed Execution Date,		3. Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3,		d (A) o) or 5. Am 4 and Secur Benet Owne		ount of ities icially d Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount		(A) or (D)	Pric	e		ted action(s) 3 and 4)			(Instr. 4)
Common Stock				07/13/	/13/2017				J ⁽¹⁾		850,00	850,000 D		(1)	4,320,348			D ⁽²⁾	
Common Stock																	60,934		D ⁽³⁾	
Common Stock														89,292			D ⁽⁴⁾			
Common Stock															7	4,293		D ⁽⁵⁾		
		Ta	able II - I (sed of, onvertib					wned				
Derivative Conversion		3. Transaction Date (Month/Day/Year) (Month/Day/Year)		on Date, Tra		ctio	on of		6. Date Exercis Expiration Date (Month/Day/Yea		•	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		;					10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	or Nu of	ımber						
		Reporting Person* /ENTURES	<u>LP</u>																	
(Last) 29 NEW		(First) EET, 3RD FLO	(Midd	dle)		_														
(Street)	J	MA	021	16		_														

THIRD RO	CK VENTURE	S LP
(Last)	(First)	(Middle)
29 NEWBURY	STREET, 3RD F	LOOR
(Street)		
BOSTON	MA	02116
(City)	(State)	(Zip)
	ress of Reporting Pers Ventures GP, L	
(Last)	(First)	(Middle)
29 NEWBURY	STREET, 3RD F	LOOR
(Street)		
BOSTON	MA	02116
(City)	(State)	(Zip)
1. Name and Addr TRV GP, LL	ress of Reporting Pers	on*
(Last)	(First)	(Middle)

,		
(Street) BOSTON	MA	02116
(City)	(State)	(Zip)
1. Name and Addi	ress of Reporting Person $\frac{1}{2}$	•
(Last) 29 NEWBURY	(First) V STREET, 3RD FLC	(Middle)
(Street) BOSTON	MA	02116
(City)	(State)	(Zip)
STARR KE (Last)	ress of Reporting Person VIN P (First) / STREET, 3RD FLC	(Middle)
(Street) BOSTON	MA	02116
(City)	(State)	(Zip)
1. Name and Addi	ress of Reporting Person DERT I	•
(Last) 29 NEWBURY	(First) / STREET, 3RD FLC	(Middle)
(Street) BOSTON		
BOSTON	MA	02116

29 NEWBURY STREET, 3RD FLOOR

Explanation of Responses:

- 1. Pursuant to a Rule 10b5-1 trading plan adopted by Third Rock Ventures, L.P. ("TRV"), TRV distributed on July 13, 2017, for no consideration, 850,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP, L.P. ("TRV GP"), the general partner of TRV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP distributed, for no consideration, the Shares it received in the distribution by TRV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.
- 2. These shares are directly held by TRV. The general partner of TRV is TRV GP. The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
- 3. These shares are directly held by Starr. Includes Shares received in the distributions described in footnote (1) above.
- $4. \ These shares are directly held by Levin. Includes Shares received in the distributions described in footnote (1) above. \\$
- 5. These shares are directly held by Tepper. Includes Shares received in the distributions described in footnote (1) above.

Remarks:

/s/ Kevin Gillis, Chief Financial Officer of TRV GP, LLC, general partner of Third Rock Ventures GP, L.P., general partner of Third Rock Ventures, L.P.	07/13/2017
/s/ Kevin Gillis, Chief Financial Officer of TRV GP, LLC, general partner of Third Rock Ventures GP, L.P.	07/13/2017
/s/ Kevin Gillis, Chief Financial Officer of TRV GP, LLC	07/13/2017
/s/ Kevin Gillis by power of attorney for Mark Levin	07/13/2017
/s/ Kevin Gillis by power of attorney for Kevin Starr	07/13/2017
/s/ Kevin Gillis by power of attorney for Robert I. Tepper	07/13/2017
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.